Stock Market Reviews

VRTX (Vertex Pharmaceuticals Incorporated) News

Get the latest news, insights, and market updates on VRTX (Vertex Pharmaceuticals Incorporated). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12
  BOSTON, December 22, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 5:15 p.m. ET/2:15 p.m. PT.
  Dec 22, 2025 - $VRTX
• 2 Cash-Producing Stocks to Consider Right Now and 1 We Find Risky
  Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
  Dec 22, 2025 - $VRTX
• 2 Reasons to Watch VRTX and 1 to Stay Cautious
  Since June 2025, Vertex Pharmaceuticals has been in a holding pattern, posting a small return of 0.5% while floating around $450.68. The stock also fell short of the S&P 500’s 13.6% gain during that period.
  Dec 18, 2025 - $VRTX
• Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
  In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $449.52, denoting a -1.2% move from the preceding trading day.
  Dec 17, 2025 - $VRTX
• Alger Russell Innovation Index Updates for Fourth Quarter 2025
  Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.
  Dec 15, 2025 - $VRTX
• Is Vertex Pharmaceuticals Fairly Priced After Recent Gains and Expanding Pipeline in 2025?
  Wondering whether Vertex Pharmaceuticals is still worth buying at around $452 a share, or if the big gains are already behind it? This article will walk you through what the numbers are really saying about its value. The stock is up 4.1% over the last month and 11.4% year to date, even though the 1 year return is slightly negative at -2.5%. This hints at a mix of renewed optimism and lingering caution after a strong 3 year gain of 48.3%. Recent attention has focused on Vertex’s expanding...
  Dec 13, 2025 - $VRTX
• How Investors Are Reacting To Vertex Pharmaceuticals (VRTX) Pediatric CASGEVY Data And Accelerated FDA Review
  Vertex Pharmaceuticals recently reported clinical data showing that CASGEVY helped all evaluable children aged 5–11 with severe sickle cell disease or transfusion‑dependent beta thalassemia meet key 12‑month endpoints, and it also received a U.S. FDA Commissioner’s National Priority Voucher to speed review for this younger age group. This combination of strong pediatric results and accelerated FDA review could meaningfully expand CASGEVY’s eligible patient pool and reinforce Vertex’s...
  Dec 13, 2025 - $VRTX
• 2 Healthcare Stocks to Buy Ahead of the New Year
  These companies could innovate their way to success.
  Dec 12, 2025 - $VRTX
• Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
  Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
  Dec 12, 2025 - $VRTX
• Earnings update: Zoom, Virgin Galactic, Nvidia, Warner Bros Discovery and more
  CFOs, including Gunnar Wiedenfels of Warner Bros. Discovery and Colette Kress of Nvidia, addressed disciplined spending, sharper personalization and AI strategy on last month's earnings calls.
  Dec 11, 2025 - $VRTX